Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

BulgariaBack to Bulgaria

Clinical trials in Dupnitsa – page 4

57 clinical trials in Dupnitsa, Bulgaria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Dupnitsa at a glance
57
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

57 trials in Dupnitsa

Open in trial search

Dermatitis atopic

Not recruiting

Study on Long-Term Safety and Efficacy of Amlitelimab for Patients with Moderate to Severe Atopic Dermatitis from Previous Trials

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Hypertriglyceridaemia+1

Not recruiting

Study of Olezarsen (ISIS 678354) for Patients with High Triglycerides and Heart Disease or Severe High Triglycerides

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:ISIS 678354 sodium salt
  • Sponsor:Ionis Pharmaceuticals Inc.

Atrial fibrillation

Not recruiting

Study on Milvexian and Apixaban for Preventing Stroke in Patients with Atrial Fibrillation

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Andexanet Alfa
  • Sponsor:Janssen Cilag International

Vitiligo

Not recruiting

Study on Ritlecitinib for Adults and Adolescents with Nonsegmental Vitiligo

Registered drug
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Pfizer Inc.

Chronic obstructive pulmonary disease

Not recruiting

A study testing tozorakimab for long-term treatment of chronic obstructive pulmonary disease in former smokers with repeated flare-ups

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol
  • Sponsor:AstraZeneca AB

Chronic obstructive pulmonary disease

Not recruiting

A Study of Inhaled Fexlamose for Adults with Moderate to Severe Chronic Obstructive Pulmonary Disease

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:6-THIO-ALFA-D-GLUCOPYRANOSYL 6-THIO-ALFA-D-GLUCOPYRANOSIDE
  • Sponsor:Aer Therapeutics Inc.

Chronic obstructive pulmonary disease

Not recruiting

Study of Tozorakimab for Patients with Chronic Obstructive Pulmonary Disease Who Have Symptoms and a History of Flare-ups

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol Sulfate
  • Sponsor:AstraZeneca AB

Dermatitis atopic

Not recruiting

Study of Rocatinlimab with Topical Treatments for Adults with Moderate to Severe Atopic Dermatitis

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Metabolic dysfunction-associated liver disease+2

Not recruiting

Comparing liquid versus capsule forms of phosphatidylcholine in patients with alcoholic liver disease, chronic hepatitis B, and metabolic liver disease

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:De-oiled enriched phospholipids from soya-beans
  • Sponsor:Opella Healthcare Group S.A.S.

Influenza immunisation

Not recruiting

Study on the Safety and Immune Response of a High-Dose Influenza Vaccine in Adults Aged 60 and Over, Comparing Trivalent Influenza Vaccine with a Drug Combination

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:A/Victoria/4897/2022 (H1N1)Pdm09-Like Strain (A/Victoria/4897/2022, Ivr-238)
  • Sponsor:Abbott Biologicals B.V.

Obesity

Not recruiting

Study on How Cagrilintide and Semaglutide Help People with Overweight or Obesity Reduce Weight

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Sponsor:Novo Nordisk A/S

Urinary tract infection+1

Not recruiting

Study of meropenem-vaborbactam safety and effectiveness in children aged 3 months to 12 years with complicated urinary tract infection or acute pyelonephritis

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:0–17 years
  • Substances:Meropenem
  • Sponsor:Rempex Pharmaceuticals Inc.

Other cities in Bulgaria

The busiest research cities in the country

All 53 cities in Bulgaria

Clinical research in Dupnitsa

What the registry says about research in the country

01 Cardiovascular & Metabolic Research

Innovative trials focusing on cardiovascular health and metabolic conditions, including studies of new treatments for obesity and heart conditions. Research aims to evaluate therapies for reducing cardiovascular risks and managing weight-related health issues.

  • Obesity and Weight Management
  • Heart Failure
  • Hypertriglyceridemia

Current studies are examining novel compounds for cardiovascular safety and weight reduction outcomes.

02 Respiratory Medicine

Advanced research in respiratory diseases, particularly focusing on chronic conditions affecting lung function. Studies evaluate new treatment combinations and their impact on patient outcomes.

  • Asthma Management
  • COPD Treatment
  • Lung Function Preservation

Trials are investigating innovative therapies to prevent lung function decline and manage exacerbations.

03 Dermatology Studies

Comprehensive research in dermatological conditions, investigating new treatments for various skin disorders. Studies focus on both chronic and acute skin conditions.

  • Atopic Dermatitis
  • Plaque Psoriasis
  • Vitiligo Treatment

Evaluating long-term safety and efficacy of novel therapeutic approaches for skin disorders.

Back to BulgariaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.